LEN vs PRCT · rev $34.19B vs rev $224.5M
LEN (LEN) versus Procept Biorobotics Corp (PRCT) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Procept Biorobotics Corp (PRCT) is a medical devices company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PRCT revenue for 2024-12-31 was $224.5M. Net income was -$91.4M. Revenue was up 64.8% from 2023-12-31 to 2024-12-31. PRCT currently screens at market cap $1.52B.
LEN currently screens at market cap $0. PRCT currently screens at market cap $1.52B.
Not investment advice. Open the LEN and PRCT stock pages for the full models.
Not investment advice.